Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine–prostaglandin E₂ cooperation

Bibliography

• Hoskin DW, Mader JS, Furlong SJ, Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008;32:527-35
   PubMed Web of Science ®Google Scholar
• Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997;57:2602-5
   PubMed Web of Science ®Google Scholar
• Sitarz R, Leguit RJ, de Leng WW, Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. Cell Oncol 2009;31:475-85
   PubMedGoogle Scholar
• Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Q, Zhang M, Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009;182:3801-8
   Google Scholar
• Toutirais O, Chartier P, Dubois D, Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003;14:246-55
   PubMed Web of Science ®Google Scholar
• Sa G, Das T, Moon C, GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009;69:3095-104
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66
   PubMed Web of Science ®Google Scholar
• Doubrovina ES, Doubrovin MM, Vider E, Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003;171:6891-9
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125:S272-83
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006;130:103-24
   PubMedGoogle Scholar
• Reichert TE, Strauss L, Wagner EM, Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45
   PubMed Web of Science ®Google Scholar
• Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin North AM 2007;16:755-74
   PubMed Web of Science ®Google Scholar
• Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009;9:3
   PubMedGoogle Scholar
• Fakhry C, Westra WH, Li S, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-12
   PubMed Web of Science ®Google Scholar
• Uppaluri R, Dunn GP, Lewis JS Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 2008;8:16
   PubMedGoogle Scholar
• Imai N, Ikeda H, Tawara I, Shiku H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur J Immunol 2009;39:241-53
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Wang Y, T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008;14:3706-15
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Gooding W, The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-11
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009;15:6348-57
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, DelVecchio MT, Regulatory (FOXP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010;33:435-41
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008;14:5947-52
   PubMed Web of Science ®Google Scholar
• Czystowska M, Strauss L, Bergmann C, Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 2010;88:577-88
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-67
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Wing K, Yamaguchi T. Dynamics of peripheral tolerance and immune regulation mediated by Treg. Eur J Immunol 2009;39:2331-6
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3+ Treg kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunology 2009;182:1469-80
   PubMed Web of Science ®Google Scholar
• Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45
   PubMed Web of Science ®Google Scholar
• Raimondi G, Turner MS, Thomson AW, Morel PA. Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol 2007;27:61-95
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Stassen M, Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-94
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, Interleukin-10 secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865-73
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Bacchetta R, Bordignon C, Type 1 T regulatory cells. Immunol Rev 2001;182:68-79
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Choudhury A, Lladsev A, Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Czystowska M, Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325-32
   PubMed Web of Science ®Google Scholar
• Suchard MS, Mayne E, Green VA, FOXP3 expression is upregulated in CD4+ T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One 2010;5:e11762
   PubMedGoogle Scholar
• Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009;21:612-18
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, A unique subset of CD4+CD25highFoxp3+ T cells secreting IL-10 and TGF-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13:4345-54
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Lukashev D, Apasov S, Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82
   PubMed Web of Science ®Google Scholar
• Dannenberg AJ, Altorki NK, Boyle JO, Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51
   PubMed Web of Science ®Google Scholar
• Dzhandzhugazyan KN, Kirkin AF, thor Straten P, Zeuthen J. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett 1998;430:227-30
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Lang S, Jackson EK, Gorelik E. Tumor-derived adenosine enhances generation and suppressive functions of human adaptive regulatory T cells. (abstract). ISBTC Ann Meeting, Washington DC, Oct 28–29, 2009
   Google Scholar
• Zhang X, Meng L, He B, The role of P2X7 receptor in ATP-mediated human leukemia cell death: calcium influx-independent. Acta Biochim Biophys Sin (Shanghai) 2009;41:362-9
   PubMed Web of Science ®Google Scholar
• Sitkovsky M, Lukashev D, Deaglio S, Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharma 2008;153:S457-64
   PubMed Web of Science ®Google Scholar
• Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;29:5346-58
   PubMed Web of Science ®Google Scholar
• Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res 2010;70:6407-11
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Hilldorfer B, Szczepanski MJ, Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010;285:7176-86
   PubMed Web of Science ®Google Scholar
• Borsellino G, Kleinewietfeld M, Di Mitri D, Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010;285:27571-80
   PubMed Web of Science ®Google Scholar
• Schuler P, Harasymczuk M, Schilling B, The identification of two phenotypically and functionally distinct subsets within the human CD4+CD39+ T cell population. J Immunol Meth 2011;369:59-68
   Google Scholar
• Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Meth 2009;346:55-63
   PubMed Web of Science ®Google Scholar
• Zhou L, Chong MW, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009;30:646-55
   PubMed Web of Science ®Google Scholar
• Zhang H, Conrad DM, Butler JJ, Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3′,5′-monophosphate and phosphatises. J Immunol 2004;173:932-44
   PubMed Web of Science ®Google Scholar
• Raskovalova T, Lokshin A, Huang X, Inhibition of cytokine production and cytotoxic activity of human anti melanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signalling. Cancer Res 2007;67:5949-56
   PubMed Web of Science ®Google Scholar
• Kameoka J, Tanaka T, Nojima Y, Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993;261:466-9
   PubMed Web of Science ®Google Scholar
• Schrader WP, West CA. Localization of adenosine deaminase and adenosine deaminase complexing protein in rabbit heart. Implications for adenosine metabolism. Circ Res 1990;66:754-62
   PubMed Web of Science ®Google Scholar
• Dong RP, Kameoka J, Hegen M, Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996;156:1349-55
   PubMed Web of Science ®Google Scholar
• Havre PA, Abe M, Urasaki Y, The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008;13:1634-45
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 2007;56:1429-42
   PubMed Web of Science ®Google Scholar
• Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22
   PubMed Web of Science ®Google Scholar
• Singh B, Cook KR, Vincent L, Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 2008;147:240-6
   PubMed Web of Science ®Google Scholar
• Yaqub S, Tasken K. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog 2008;14:57-77
   PubMedGoogle Scholar
• Su Y, Huang X, Raskovalova T, Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 2008;57:1611-23
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-17
   PubMed Web of Science ®Google Scholar
• Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 2011;60:111-22
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Exp Opin Biol Ther 2010;10:1019-35
   PubMed Web of Science ®Google Scholar
• Hasko G, Linden J, Cronstein B, Adenosine receptors: therapeutic aspects for inflammatory and immune disease. Nat Rev Drug Discov 2008;7:759-70
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Metronomic cyclophosphamide regimen selectively depicts CD4+CD25+ regulatory T cells and restores T and NK effector functions in early stage cancer patients. Cancer Immunol Immunother 2007;56:641-8
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T, Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines. Blood 2008;112:610-18
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar
• DeVries IJM, Castelli C, Huygens C, Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2010;17:1-8
   Google Scholar
• Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 2010;185:1993-8
   PubMed Web of Science ®Google Scholar
• Greenhough A, Smartt HJM, Moore AE, The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377-86
   PubMed Web of Science ®Google Scholar
• Iwatsubo K, Okumura S, Ishikawa Y. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr Metab Immune Disord Drug Targets 2006;6:239-47
   PubMedGoogle Scholar
• Pavan B, Biondi C, Dalpiaz A. Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today 2009;14:982-91
   PubMed Web of Science ®Google Scholar
• Duan B, Davis R, Sadat EL, Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice. J Immunol 2010;185:335-44
   PubMed Web of Science ®Google Scholar